In the past week, SYRS stock has gone down by -9.14%, with a monthly decline of -2.98% and a quarterly plunge of -87.69%. The volatility ratio for the week is 14.40%, and the volatility levels for the last 30 days are 14.56% for Syros Pharmaceuticals Inc The simple moving average for the past 20 days is 7.68% for SYRS’s stock, with a -92.63% simple moving average for the past 200 days.
Is It Worth Investing in Syros Pharmaceuticals Inc (NASDAQ: SYRS) Right Now?
SYRS has 36-month beta value of 1.32. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for SYRS is 17.43M, and currently, short sellers hold a 6.31% ratio of that float. The average trading volume of SYRS on January 15, 2025 was 9.51M shares.
SYRS) stock’s latest price update
The stock of Syros Pharmaceuticals Inc (NASDAQ: SYRS) has increased by 11.97 when compared to last closing price of 0.21.Despite this, the company has seen a loss of -9.14% in its stock price over the last five trading days. zacks.com reported 2024-11-14 that SYRS stock plummets as late-stage cancer study of lead candidate fails to achieve its primary endpoint leading to the termination of the study.
Analysts’ Opinion of SYRS
Many brokerage firms have already submitted their reports for SYRS stocks, with H.C. Wainwright repeating the rating for SYRS by listing it as a “Buy.” The predicted price for SYRS in the upcoming period, according to H.C. Wainwright is $15 based on the research report published on November 04, 2020 of the previous year 2020.
Alliance Global Partners, on the other hand, stated in their research note that they expect to see SYRS reach a price target of $18. The rating they have provided for SYRS stocks is “Buy” according to the report published on September 22nd, 2020.
SYRS Trading at -64.21% from the 50-Day Moving Average
After a stumble in the market that brought SYRS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -97.02% of loss for the given period.
Volatility was left at 14.56%, however, over the last 30 days, the volatility rate increased by 14.40%, as shares surge +1.78% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -90.44% lower at present.
During the last 5 trading sessions, SYRS fell by -8.22%, which changed the moving average for the period of 200-days by -95.89% in comparison to the 20-day moving average, which settled at $0.2208. In addition, Syros Pharmaceuticals Inc saw 3.39% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SYRS starting from AKKARAJU SRINIVAS, who proposed sale 9,333 shares at the price of $0.25 back on Dec 30 ’24. After this action, AKKARAJU SRINIVAS now owns shares of Syros Pharmaceuticals Inc, valued at $2,306 using the latest closing price.
Flagship Pioneering Fund VII,, the Affiliate of Syros Pharmaceuticals Inc, proposed sale 1,331,624 shares at $0.21 during a trade that took place back on Dec 27 ’24, which means that Flagship Pioneering Fund VII, is holding shares at $279,641 based on the most recent closing price.
Stock Fundamentals for SYRS
Current profitability levels for the company are sitting at:
- -288.92 for the present operating margin
- -2.29 for the gross margin
The net margin for Syros Pharmaceuticals Inc stands at -253.41. The total capital return value is set at -1.97. Equity return is now at value -776.96, with -84.04 for asset returns.
Based on Syros Pharmaceuticals Inc (SYRS), the company’s capital structure generated 1.23 points at debt to capital in total, while cash flow to debt ratio is standing at -1.66. The debt to equity ratio resting at -5.41. The interest coverage ratio of the stock is -20.92.
Currently, EBITDA for the company is -157.19 million with net debt to EBITDA at -0.02. When we switch over and look at the enterprise to sales, we see a ratio of 21.57. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.25.
Conclusion
To put it simply, Syros Pharmaceuticals Inc (SYRS) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
